AC Immune (ACIU) Capital Expenditures (2015 - 2025)
AC Immune (ACIU) posted quarterly Capital Expenditures of -$133875.2 for Q4 2025, down 30.31% year-over-year from -$192097.3 in Q4 2024, and down 84.64% quarter-over-quarter from -$72506.4 in Q3 2025.
Powered by 
Analysis
AC Immune (ACIU) Capital Expenditures (2015 - 2025) Analysis & Trends
AC Immune (ACIU) has reported Capital Expenditures for 11 consecutive years, with -$133875.2 the latest figure, recorded in Q4 2025.
- In Q4 2025, Capital Expenditures fell 30.31% year-over-year to -$133875.2; the TTM figure through Dec 2025 stood at -$1.1 million (down 60.96% YoY), while the FY2025 annual figure was -$1.1 million, down 65.09% from the prior year.
- Capital Expenditures fell to -$133875.2 in Q4 2025 per ACIU's latest filing, from -$72506.4 in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.9 million in Q4 2021 and bottomed at -$873786.7 in Q1 2021.
- Historically, Capital Expenditures has averaged $74110.8 across 5 years, with a median of -$205646.8 in 2023.
- Annual changes were most pronounced in 2022 — Capital Expenditures soared 76.76% — and 2025, when it slumped 499.17%.
- AC Immune's Capital Expenditures stood at $4.9 million in 2021, then slumped by 48.71% to $2.5 million in 2022, then tumbled by 107.4% to -$187140.8 in 2023, then jumped by 45.1% to -$102737.0 in 2024, then plunged by 30.31% to -$133875.2 in 2025.
- Business Quant data shows ACIU's Capital Expenditures at -$133875.2 in Q4 2025, -$72506.4 in Q3 2025, and -$450543.1 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | AC Immune | 285.13 Mn | 285.13 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -133,875.17 |
| Sep 30, 2025 | -72,506.35 |
| Jun 30, 2025 | -450,543.06 |
| Mar 31, 2025 | -402,634.69 |
| Dec 31, 2024 | -102,736.97 |
| Sep 30, 2024 | -195,061.02 |
| Jun 30, 2024 | -75,193.96 |
| Mar 31, 2024 | -285,274.90 |
| Dec 31, 2023 | -187,140.84 |
| Sep 30, 2023 | -317,002.72 |
| Jun 30, 2023 | -172,387.21 |
| Mar 31, 2023 | -216,232.52 |
| Dec 31, 2022 | -42,558.90 |
| Sep 30, 2022 | -125,290.25 |
| Jun 30, 2022 | -557,563.34 |
| Mar 31, 2022 | -584,716.52 |
| Dec 31, 2021 | -783,010.51 |
| Sep 30, 2021 | -539,118.91 |
| Jun 30, 2021 | -688,694.39 |
| Mar 31, 2021 | -873,786.66 |